Beximco Pharmaceuticals Limited (LON:BXP - Get Free Report)'s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 37.42 ($0.51) and traded as high as GBX 40 ($0.54). Beximco Pharmaceuticals shares last traded at GBX 40 ($0.54), with a volume of 35,010 shares changing hands.
Beximco Pharmaceuticals Stock Down 3.0%
The company has a 50-day simple moving average of GBX 37.39 and a 200 day simple moving average of GBX 37.34. The company has a market cap of £25.45 billion, a P/E ratio of 4.01 and a beta of 0.61. The company has a current ratio of 2.13, a quick ratio of 0.37 and a debt-to-equity ratio of 12.47.
About Beximco Pharmaceuticals
(
Get Free Report)
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.
See Also
Before you consider Beximco Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beximco Pharmaceuticals wasn't on the list.
While Beximco Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
